Skip to main content
Premium Trial:

Request an Annual Quote

Atugen Gets Rights to Isis Antisense

NEW YORK, Jan. 16-Atugen has secured a license to Isis Pharmaceuticals' antisense-based functional genomics techniques, the two companies said today.

 

Atugen, which has its own functional genomics technology to reduce expression in selected genes, will be able to use Isis' techniques for discovery and validation of both targets and compounds for itself and for its customers.

 

Isis' functional genomics technologies, held by its GeneTrove division, include antisense inhibitors that work through RNAse H, a naturally occurring cellular enzyme that cleaves the RNA portion of an RNA/DNA duplex.

 

The deal complements Atugen's existing services in siRNA, transfection and gene expression reduction, the Berlin-based company said in a statement. Atugen has obtained licenses from various companies for antisense and RNA interference technologies.

 

Isis Pharmaceuticals is based in Carlsbad, Calif. It is a public company.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.